Statins in primary prophylaxis of cardiovascular diseases


Cite item

Full Text

Abstract

The review summarises data on statins efficacy in primary prophylaxis of cardiovascular complications. Main results of the JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial are analysed in detail. Its role in possible changes in current recommendations on prophylaxis and treatment of atherosclerosis is shown. Statins are considered as drugs essential in the strategy of improvement of life quality.

About the authors

Zhanna Davidovna Kobalava

Svetlana Vadimovna Villeval'de

Email: villevaldes@mail.ru

G D Kobalava

Russian University of Peoples' Friendship, Moscow

Russian University of Peoples' Friendship, Moscow

S V Villevalde

Russian University of Peoples' Friendship, Moscow

Russian University of Peoples' Friendship, Moscow

References

  1. Национальные рекомендации по кардиоваскулярной профилактике в клинической практике (проект.). http://scardio.ru/recommendations/draft001CD/default.asp
  2. Оганов Р. Г. (ред.) Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза: Нац. клинические рекомендации. Сборник. 3-е изд. М.: Изд-во "Силицея-Полиграф"; 2010. 192-274.
  3. Grundy S. M., Cleeman J. I., Merz C. N. et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications or recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; l10: 227-239.
  4. European guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prevent. Rehabil. 2007; 4 (Suppl. 2).
  5. Ridker P. M., Danielson E., Fonseca F. et al for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-2207.
  6. Hlatky M. A. Expanding the orbit of primary prevention - moving beyond JUPITER. N. Engl. J. Med. 2008; 359: 2280- 2282.
  7. Ridker P. M., Danielson E., Fonseca F. A. H. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
  8. Glynn R. J., Danielson E., Fonseca F. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009; 360: 1851-1861.
  9. Everett B. M., Glynn R. J., MacFadyen J. G., Ridker P. M. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein. Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010; 121: 143-150.
  10. Goldstein L. B., Bushnell C. D., Adams R. J. et al. Guidelines for the primary prevention of stroke. A Guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, published online Dec 6, 2010; http://stroke.ahajournals.org, doi:10.1161/ STR.0b013e3181fcb238.
  11. Glynn R. J., Koenig W., Nordestgaard B. G. et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann. Intern. Med. 2010; 152(8): 488-496.
  12. Mora S., Glynn R. J., Hsia J. et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121: 1069-1077.
  13. Ridker P. M., MacFadyen J., Cressman M., Glynn R. J. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein. A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial. J. Am. Coll. Cardiol. 2010; 55: 1266-1273.
  14. Ridker P. M., MacFadyen J. G., Nordestgaard B. G. et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for "Intermediate Risk". Circ. Cardiovasc. Qual. Outcomes 2010; 3: 447-452.
  15. Ridker P. M., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 2001; 344: 1959-1965.
  16. Yang E. Y., Nambi V., Tang Z. et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a US Population: insights from the ARIC (Atherosclerosis Risk in Communities) Study. J. Am. Coll. Cardiol. 2009; 54: 2388-2395.
  17. McMurray J. J. V., Kjekshus J., Gullestad L. et al. for the CORONA Study Group. Effects of statin therapy according to plasma highsensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009; 120: 2188-2196.
  18. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2010; 56(25): 2l82-2199.
  19. Genest J., McPherson R., Frohlich J. et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention or cardiovascular disease in the adult - 2009 recommendations. Can. J. Cardiol. 2009; 25(10): 567-579.
  20. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200128.htm
  21. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm199891.htm
  22. Ridker P. M., Glynn R. J. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 2010; 375: 2071.
  23. Brugts J. J., Yetgin T., Hoeks S. E. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Br. Med. J. 2009; 338: b2376.
  24. Ray K. K., Seshasai S. R. K., Erqou S. et al. Statins and all-cause mortality in high-risk primary prevention. A meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch. Intern. Med. 2010; 170: 1024-1031.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies